Prognostic value of translationally controlled tumor protein in colon cancer

Stoyanov,Dragomir Svetozarov; Conev,Nikolay Vladimirov; Penkova-Ivanova,Mariya Ivanova; Donev,Ivan Shterev

doi:10.3892/mco.2023.2668

Prognostic value of translationally controlled tumor protein in colon cancer

Authors:
- Dragomir Svetozarov Stoyanov
- Nikolay Vladimirov Conev
- Mariya Ivanova Penkova-Ivanova
- Ivan Shterev Donev
View Affiliations

Affiliations: Department of Oncology, Medical University Varna, Varna 9002, Bulgaria, Clinic of Medical Oncology, Nadezhda Hospital, Sofia 1330, Bulgaria
Published online on: July 24, 2023 https://doi.org/10.3892/mco.2023.2668
Article Number: 72
Copyright: © Stoyanov et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The translationally controlled tumor protein (TCTP) is a highly conserved protein involved in a variety of normal cell functions and disease processes. Preclinical studies revealed that TCTP has anti‑apoptotic properties, promotes cell growth and division and is involved in cancer progression by promoting invasion and metastasis. The present study explored the potential value of TCTP as a prognostic marker in colon cancer. A retrospective analysis of 74 patients with colon cancer was performed. Using immunohistochemistry, TCTP levels in the primary tumor were assessed semi‑quantitatively by the calculation of cytoplasmic and nuclear H‑score. Cytoplasmic TCTP levels in the primary tumor had no statistically significant association with disease‑free survival (DFS), progression‑free survival (PFS) and overall survival (OS) in the present patient population. Patients whose primary tumors had a negative nuclear TCTP expression had significantly improved clinical outcomes. The PFS for the negative nuclear TCTP expression group was 7.7 months [95% confidence interval (CI), 5.8‑9.5] compared with 5.5 months (95% CI, 3.2‑7.8) in the group with positive nuclear expression (P=0.023, Mantel‑Cox log‑rank). Patients with a negative nuclear expression of TCTP had a significantly higher median OS (22.2 months; 95% CI, 16.1‑28.3) compared with those with positive TCTP nuclear expression (median 13.2 months; 95% CI, 10.1‑16.3; P=0.008, Mantel‑Cox log‑rank). In a multivariate Cox regression model, a positive nuclear TCTP H‑score was an independent risk factor for worse PFS and OS. The 1‑year OS rate in the group with negative nuclear TCTP expression was 86.3% compared with 56.5% in patients with positive nuclear TCTP expression (P=0.008). The present study suggested that semiquantitative H‑score measurement of TCTP levels in the nuclei of tumor cells from the primary tumor is a potential prognostic marker for clinical outcomes in patients with colon cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Xi Y and Xu P: Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 14(101174)2021.PubMed/NCBI View Article : Google Scholar
3	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.PubMed/NCBI View Article : Google Scholar
4	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020.PubMed/NCBI View Article : Google Scholar
5	Punt CJA, Koopman M and Vermeulen L: From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 14:235–246. 2017.PubMed/NCBI View Article : Google Scholar
6	Bommer UA and Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol. 36:379–385. 2004.PubMed/NCBI View Article : Google Scholar
7	Thiele H, Berger M, Skalweit A and Thiele BJ: Expression of the gene and processed pseudogenes encoding the human and rabbit translationally controlled tumour protein (TCTP). Eur J Biochem. 267:5473–5481. 2000.PubMed/NCBI View Article : Google Scholar
8	Bommer UA, Borovjagin AV, Greagg MA, Jeffrey IW, Russell P, Laing KG, Lee M and Clemens MJ: The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA. 8:478–496. 2002.PubMed/NCBI View Article : Google Scholar
9	Nielsen HV, Johnsen AH, Sanchez JC, Hochstrasser DF and Schiøtz PO: Identification of a basophil leukocyte interleukin-3-regulated protein that is identical to IgE-dependent histamine-releasing factor. Allergy. 53:642–652. 1998.PubMed/NCBI View Article : Google Scholar
10	Thaw P, Baxter NJ, Hounslow AM, Price C, Waltho JP and Craven CJ: Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol. 8:701–704. 2001.PubMed/NCBI View Article : Google Scholar
11	Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T and Bommer UA: The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci. 112:1257–1271. 1999.PubMed/NCBI View Article : Google Scholar
12	Li F, Zhang D and Fujise K: Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem. 276:47542–47549. 2001.PubMed/NCBI View Article : Google Scholar
13	Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R and Telerman A: Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA. 99:14976–14981. 2002.PubMed/NCBI View Article : Google Scholar
14	Rho SB, Lee JH, Park MS, Byun HJ, Kang S, Seo SS, Kim JY and Park SY: Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 585:29–35. 2011.PubMed/NCBI View Article : Google Scholar
15	Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, Colaluca I, Viale G, Rodrigues-Ferreira S, Wynendaele J, et al: Reciprocal repression between P53 and TCTP. Nat Med. 18:91–99. 2011.PubMed/NCBI View Article : Google Scholar
16	Lucibello M, Gambacurta A, Zonfrillo M, Pierimarchi P, Serafino A, Rasi G, Rubartelli A and Garaci E: TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res. 317:2479–2489. 2011.PubMed/NCBI View Article : Google Scholar
17	Sinha P, Kohl S, Fischer J, Hütter G, Kern M, Köttgen E, Dietel M, Lage H, Schnölzer M and Schadendorf D: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis. 21:3048–3057. 2000.PubMed/NCBI View Article : Google Scholar
18	Graidist P, Phongdara A and Fujise K: Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity. J Biol Chem. 279:40868–40875. 2004.PubMed/NCBI View Article : Google Scholar
19	Chan THM, Chen L and Guan XY: Role of translationally controlled tumor protein in cancer progression. Biochem Res Int. 2012(369384)2012.PubMed/NCBI View Article : Google Scholar
20	Telerman A and Amson R: The molecular programme of tumour reversion: The steps beyond malignant transformation. Nat Rev Cancer. 9:206–216. 2009.PubMed/NCBI View Article : Google Scholar
21	Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafrè S, Carcangiu ML, Zonfrillo M, Nicotera G, Sica L, De Braud F and Pierimarchi P: Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. Oncotarget. 6:5275–5291. 2015.PubMed/NCBI View Article : Google Scholar
22	Ma Q, Geng Y, Xu W, Wu Y, He F, Shu W, Huang M, Du H and Li M: The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells. J Proteome Res. 9:40–49. 2010.PubMed/NCBI View Article : Google Scholar
23	Miao X, Chen YB, Xu SL, Zhao T, Liu JY, Li YR, Wang J, Zhang J and Guo GZ: TCTP overexpression is associated with the development and progression of glioma. Tumour Biol. 34:3357–3361. 2013.PubMed/NCBI View Article : Google Scholar
24	Amson R, Pece S, Marine JC, Di Fiore PP and Telerman A: TPT1/TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol. 23:37–46. 2013.PubMed/NCBI View Article : Google Scholar
25	Zhang D, Li F, Weidner D, Mnjoyan ZH and Fujise K: Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem. 277:37430–37438. 2002.PubMed/NCBI View Article : Google Scholar
26	Xiao B, Chen D, Luo S, Hao W, Jing F, Liu T, Wang S, Geng Y, Li L, Xu W, et al: Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/MMP9 signaling. Oncotarget. 7:50057–50073. 2016.PubMed/NCBI View Article : Google Scholar
27	Fischer N, Saeed MEM, Lippe E, Roth W and Efferth T: High TCTP expression as prognostic factor in different cancer types. World Acad Sci J. 3(3)2021.
28	McCarty K Jr, Miller LS, Cox EB, Konrath J and McCarty K Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 109:716–721. 1985.PubMed/NCBI
29	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
30	Chan THM, Chen L, Liu M, Hu L, Zheng BJ, Poon VK, Huang P, Yuan YF, Huang JD, Yang J, et al: Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development. Hepatology. 55:491–505. 2012.PubMed/NCBI View Article : Google Scholar
31	Chen C, Deng Y, Hua M, Xi Q, Liu R, Yang S, Liu J, Zhong J, Tang M, Lu S, et al: Expression and clinical role of TCTP in epithelial ovarian cancer. J Mol Histol. 46:145–156. 2015.PubMed/NCBI View Article : Google Scholar
32	Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, et al: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA. 101:15364–15369. 2004.PubMed/NCBI View Article : Google Scholar
33	Gnanasekar M, Thirugnanam S, Zheng G, Chen A and Ramaswamy K: Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. Int J Oncol. 34:1241–1246. 2009.PubMed/NCBI
34	Bommer UA, Vine KL, Puri P, Engel M, Belfiore L, Fildes K, Batterham M, Lochhead A and Aghmesheh M: Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal. 15(9)2017.PubMed/NCBI View Article : Google Scholar